Drug Profile
Research programme: oncolytic viruses - Virttu Biologics
Alternative Names: HSV-1716 variant; HSV-1716/NAT; HSV-1716Ing4; HSV-1790Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Virttu Biologics
- Class Gene therapies; Oncolytic viruses; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 28 Sep 2016 Preclinical development is ongoing in United Kingdom (Virttu Biologics pipeline, September 2016)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom